Wednesday, July 8, 2026

pharma · Hemorrhoids · Persistent or Recurrent Cutaneous T-Cell Lymphoma · CTOR

CITIUS ONCOLOGY

CITIUS ONCOLOGY clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cranford, USA HQ
2024 Founded
5 Employees
Public company Type
CTOR · NYSE Ticker
Company details
Status
Public
HQ
Cranford, USA
Founded
2024
Employees
5
Programs
3
Drugs
8
Patents
0
Intelligence · Clinical Programs

CITIUS ONCOLOGY projects

1 ClinicalTrials.gov programs sponsored by CITIUS ONCOLOGY.

CITIUS ONCOLOGY has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. E7777 9 mcg/kg

    CITIUS ONCOLOGY, INC.

    Persistent or Recurrent Cutaneous T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does CITIUS ONCOLOGY have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.